GHRP-2 vs GHRP-6
Two first-generation GHRPs with similar mechanisms but notably different side effect profiles—GHRP-2 offers cleaner GH release while GHRP-6 stimulates stronger appetite.
Last updated: 2026-02-02
GHRP-2 (Growth Hormone Releasing Peptide-2) and GHRP-6 (Growth Hormone Releasing Peptide-6) are synthetic hexapeptides that stimulate growth hormone release through activation of the ghrelin receptor (GHS-R1a). Developed in the 1990s, these were among the first generation of growth hormone secretagogues and remain widely studied peptides in GH research.
Both peptides trigger pulsatile GH release that mimics natural physiology, unlike exogenous HGH which provides continuous levels. However, they differ significantly in their side effect profiles, potency, and effects on appetite, cortisol, and prolactin—making the choice between them an important consideration for research protocols.
This comprehensive comparison examines the molecular differences, research findings, theoretical protocols, and practical considerations when choosing between GHRP-2 and GHRP-6 for growth hormone research.
**Important Disclaimer:** This content is for educational and research purposes only. Neither GHRP-2 nor GHRP-6 is approved for human therapeutic use by the MHRA, EMA, or FDA. Both are prohibited in competitive sports by WADA.
Quick Comparison Table
| Category | GHRP-2 | GHRP-6 |
|---|---|---|
| Peptide Class | Growth Hormone Releasing Peptide (GHRP) | Growth Hormone Releasing Peptide (GHRP) |
| Structure | Synthetic hexapeptide (6 amino acids) | Synthetic hexapeptide (6 amino acids) |
| Primary Receptor | GHS-R1a (Ghrelin receptor) | GHS-R1a (Ghrelin receptor) |
| GH Release Potency | Moderate-High (dose-dependent) | Moderate (slightly lower than GHRP-2) |
| Appetite Stimulation | Minimal to none | Strong (ghrelin-mimetic effect) |
| Cortisol Elevation | Mild (transient) | More pronounced (dose-dependent) |
| Prolactin Elevation | Minimal | Moderate (dose-dependent) |
| Half-Life | ~15-30 minutes | ~15-20 minutes |
| Administration | Subcutaneous or intramuscular injection | Subcutaneous or intramuscular injection |
| Timing Sensitivity | Administer on empty stomach (2-3 hours post-meal) | Administer on empty stomach (2-3 hours post-meal) |
| Common Research Use | Clean GH release, anti-ageing research | GH release with appetite support, recovery research |
| Regulatory Status | Research compound only (not approved for human use) | Research compound only (not approved for human use) |
GHS-R1a Activation: Similar Receptor, Different Downstream Effects
GHRP-2
GHRP-2 Mechanism of Action
GHRP-2 (pralmorelin) binds to the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor activated by the endogenous hormone ghrelin. This binding triggers a signalling cascade in pituitary somatotrophs that results in growth hormone release.
Key Mechanistic Features:
• **Selective GH Release:** GHRP-2 demonstrates relatively selective action on GH release with minimal effects on other pituitary hormones. Prolactin and cortisol elevations are transient and dose-dependent.
• **Calcium Signalling:** Receptor activation triggers phospholipase C activation, IP3 formation, and calcium release from intracellular stores, leading to GH vesicle exocytosis.
• **Hypothalamic Effects:** GHRP-2 also acts at the hypothalamic level, stimulating GHRH neurons and potentially inhibiting somatostatin release, amplifying the GH response.
• **Partial Ghrelin Mimetic:** While activating GHS-R1a, GHRP-2 does not fully replicate ghrelin's orexigenic (appetite-stimulating) effects, making it "cleaner" in terms of side effects.
• **Synergy with GHRH:** GHRP-2 shows synergistic effects when combined with GHRH analogues (like CJC-1295 or Mod GRF 1-29), producing GH pulses 5-10x baseline levels.
Research Advantage: GHRP-2's relatively selective GH-releasing action makes it preferred in research where appetite stimulation or hormonal disruption would confound results.
GHRP-6
GHRP-6 Mechanism of Action
GHRP-6 was one of the first synthetic GHRPs developed and binds to the same GHS-R1a receptor as GHRP-2. However, its structural differences result in a broader activation profile with more pronounced effects on appetite and other hormones.
Key Mechanistic Features:
• **Strong Ghrelin Mimetic:** GHRP-6 more closely mimics endogenous ghrelin's effects, particularly the potent appetite-stimulating action. Users consistently report intense hunger within 20-30 minutes of administration.
• **Broader Hormonal Effects:** Beyond GH release, GHRP-6 causes more significant elevations in cortisol and prolactin compared to GHRP-2. These effects are dose-dependent and generally transient.
• **Gastric Motility:** The strong ghrelin-mimetic action means GHRP-6 also affects gastric motility and gastric acid secretion, which may be beneficial or problematic depending on research goals.
• **IGF-1 Elevation:** Like all GHRPs, GHRP-6 indirectly elevates IGF-1 through GH-mediated hepatic synthesis. The pulsatile GH release pattern maintains physiological IGF-1 rhythms.
• **Cardioprotective Research:** Interestingly, GHRP-6 has been studied for cardioprotective effects independent of GH release, potentially through direct cardiac GHS-R1a activation.
Research Consideration: GHRP-6's appetite-stimulating effect can be advantageous in research involving recovery, muscle building, or conditions with reduced food intake. However, it may be problematic for body composition or fasting studies.
Clinical Trial Evidence
GHRP-2 Clinical Studies
Design: Randomised controlled trial
Growth retardation in yaks was primarily due to somatotropic axis hormones secretion deficiency. Both GHRP-2 and CS administration can accelerate growth performance and GH, IGF-1 secretion in yaks with growth retardation. GHRP-2 enhanced muscle protein deposition mainly by up-regulated the protein synthesis pathways, whereas CS worked mainly by down-regulated the ubiquitin-proteasome pathway.
View study — PubMed 26894743Design: Randomised controlled trial
002). In conclusion, a paradigm examining GHRH-GHRP synergy under a sex steroid clamp reveals highly selective control of basal, pulsatile, and synergistic peptide-driven GH secretion by AVF, E(2), and IGF-I in healthy men.
View study — PubMed 19240251Design: Randomised controlled trial
Participants: 7 participants
Duration: 5 days
Coadministration of GHRP-2, TRH and GnRH reactivated the GH, TSH and LH axes in prolonged critically ill men and evoked beneficial metabolic effects which were absent with GHRP-2 infusion alone and only partially present with GHRP-2 + TRH. These data underline the importance of correcting the multiple hormonal deficits in patients with prolonged critical illness to counteract the hypercatabolic state.
View study — PubMed 12030918Design: Randomised controlled trial
In conclusion, the present results demonstrate that in humans Tyr-Ala-HEX is a GH secretagogue as potent as HEX and GHRP-2, two GHRP-6 superanalogs. Tyr-Ala-HEX also shares with HEX and GHRP-2 the same PRL- ACTH- and cortisol-releasing activity.
View study — PubMed 10195374GHRP-6 Clinical Studies
Design: Randomised controlled trial
This suggests that thyroid hormone excess interferes with GH-releasing pathways activated by these peptides. Our results also suggest that ghrelin's ability to increase glucose levels is not altered in thyrotoxicosis.
View study — PubMed 17410412Design: Randomised controlled trial
Participants: 9 participants
These data show that GH responses to GHRP-6 are much greater than to GHRH in late adulthood. The marked increase of plasma GH levels observed after administration of GHRP-6 alone or in combination with GHRH indicates that impaired GH secretion in late adulthood is a functional and potentially reversible state.
View study — PubMed 7734029Design: Clinical trial
It is concluded that hyperglycemia significantly reduces GH response to combined administration of GHRH+GHRP-6 in normal weight patients with type 2 diabetes. It is suggested that ambient glucose levels should be taken into account during interpretation of GH response to combined administration of GHRH+GHRP-6 in patients with type 2 diabetes.
View study — PubMed 14693411Design: Review
The results using insulin, IGF-I and GHRP-6 given topically are particularly intriguing. Whether these results can be replicated in humans and whether the use of these drugs for potential treatment of obesity will be commercially viable will be particularly interesting.
View study — PubMed 21413905Benefits Comparison
GHRP-2 Unique Benefits
- Cleaner GH release profile with minimal appetite stimulation
- Lower cortisol and prolactin elevation compared to GHRP-6
- Better suited for body composition and fat loss research protocols
- Reduced gastrointestinal side effects (less gastric acid, less bloating)
- Preferred for anti-ageing research due to cleaner hormonal profile
- More consistent GH response without hunger-related variables
- Better tolerated for multiple daily dosing protocols
Shared Benefits
- Pulsatile GH release mimicking natural physiology
- Synergistic effects when combined with GHRH analogues
- Maintenance of natural GH feedback mechanisms
- Elevation of IGF-1 through endogenous GH stimulation
- Potential support for tissue repair and recovery research
- Improved sleep quality observed in some research subjects
- Both extensively studied with substantial literature base
- Short half-lives allow precise timing control
GHRP-6 Unique Benefits
- Strong appetite stimulation supports caloric surplus goals
- Potentially beneficial for recovery from illness or injury (increased food intake)
- Studied for cardioprotective effects independent of GH release
- May support muscle-building research through increased nutrient intake
- Well-researched with extensive published literature
- Established safety profile from decades of research
- Lower cost per milligram in most research markets
Research & Evidence
GHRP-2 Research
GHRP-2 Research Summary
GHRP-2 (also known as pralmorelin or KP-102) has been extensively studied, including several human clinical trials, making it one of the better-characterised GHRPs.
Key Clinical Findings:
• Dose-Response Relationship: Human studies demonstrated clear dose-dependent GH release, with saturation occurring around 100-300 mcg. Higher doses did not proportionally increase GH output.
• GHRH Synergy Study (1997): Co-administration with GHRH produced GH peaks 5-10 times greater than either peptide alone, establishing the synergy principle used in modern research protocols.
• Anti-Ageing Research: Studies in elderly subjects showed GHRP-2 could restore youthful GH pulse amplitudes, suggesting potential applications in age-related GH decline.
• Minimal Tachyphylaxis: Unlike some secretagogues, GHRP-2 showed maintained efficacy over extended administration periods without significant receptor desensitisation.
• Metabolic Studies: Research indicated improvements in body composition parameters, nitrogen retention, and potentially glucose homeostasis, though more data is needed.
Published Studies: - Bowers CY et al. "On the actions of the growth hormone-releasing hexapeptide, GHRP" (Endocr J. 1997) - Arvat E et al. "Diagnostic and therapeutic uses of growth hormone-releasing substances" (Horm Res. 1998)
Research Status: GHRP-2 remains investigational but has more human data than many newer secretagogues.
GHRP-6 Research
GHRP-6 Research Summary
GHRP-6 was developed earlier than GHRP-2 and has an even longer research history, though GHRP-2 was subsequently developed to address some of GHRP-6's limitations.
Key Clinical Findings:
• First-Generation GHRP: As one of the earliest synthetic GHRPs, GHRP-6 established many fundamental concepts about GH secretagogue pharmacology that inform current research.
• Appetite and Ghrelin Research: GHRP-6 studies were instrumental in understanding the relationship between GHS-R1a activation and appetite regulation, contributing to ghrelin research.
• Cardioprotective Studies: Cuban research extensively studied GHRP-6 for cardioprotection, showing potential benefits in ischemia/reperfusion models independent of GH effects.
• Wound Healing: Topical and systemic GHRP-6 has been studied for wound healing, with some positive results in chronic wound models.
• Hormonal Profile Studies: Research documented the cortisol and prolactin elevations associated with GHRP-6, leading to development of "cleaner" alternatives like GHRP-2 and ipamorelin.
Published Studies: - Bowers CY. "Growth hormone-releasing peptide (GHRP)" (Cell Mol Life Sci. 1998) - García del Barco-Herrera D et al. "GHRP-6 and wound healing" (Growth Horm IGF Res. 2013) - Berlanga J et al. "Cardioprotective effects of GHRP-6" (Eur J Pharmacol. 2007)
Research Status: Extensive preclinical and some clinical data available. Cardioprotective research has been particularly active.
Head-to-Head Analysis
GHRP-2 vs GHRP-6: Direct Comparisons
Several studies have directly compared these peptides, revealing consistent patterns:
GH Release Potency: Most comparative studies show GHRP-2 produces slightly higher GH release than GHRP-6 at equivalent doses. One study found GHRP-2 at 100 mcg produced comparable GH output to GHRP-6 at 150 mcg.
Side Effect Profile: Head-to-head comparisons consistently demonstrate GHRP-6's stronger appetite stimulation and greater cortisol/prolactin elevation. GHRP-2 was specifically developed as a "cleaner" alternative.
Clinical Development: GHRP-2 (as pralmorelin) progressed further in clinical development, receiving diagnostic approval in Japan for GH deficiency testing. GHRP-6 has not achieved similar regulatory milestones.
Synergy Equivalence: When combined with GHRH analogues, both peptides show similar synergistic amplification of GH release. The choice between them in combined protocols often comes down to side effect preferences.
Cost-Effectiveness: GHRP-6 is typically less expensive per milligram, which may influence research budget decisions for large-scale studies.
Conclusion from Comparative Data: For pure GH stimulation research with minimal confounding variables, GHRP-2 is generally preferred. For research where appetite stimulation is desirable or not problematic, GHRP-6 offers a cost-effective alternative with extensive literature support.
Protocol Comparison
GHRP-2 Protocol
GHRP-2 Theoretical Research Protocols
Educational purposes only—not medical advice. Consult a qualified healthcare professional.
Standard Monotherapy Protocol: • Dosage: 100-300 mcg per administration (saturation dose ~100 mcg per kg/day) • Frequency: 2-3 times daily (upon waking, post-workout, before bed) • Timing: On empty stomach, 2-3 hours after last meal • Duration: 8-16 week research cycles typical
Combination with GHRH Analogue (Enhanced Protocol): • GHRP-2: 100 mcg • Mod GRF 1-29: 100 mcg (administered simultaneously) • Frequency: 2-3 times daily • Expected: 5-10x baseline GH release
Timing Considerations: • Pre-bed dosing may enhance sleep-associated GH pulse • Post-exercise dosing capitalises on natural GH release window • Avoid carbohydrate intake within 30 minutes (insulin blunts GH)
Saturation Dose Principle: Research suggests GH response plateaus around 100 mcg per administration. Higher doses increase side effects without proportional GH benefit. Multiple daily doses are more effective than single large doses.
GHRP-6 Protocol
GHRP-6 Theoretical Research Protocols
Educational purposes only—not medical advice. Consult a qualified healthcare professional.
Standard Monotherapy Protocol: • Dosage: 100-150 mcg per administration • Frequency: 2-3 times daily • Timing: On empty stomach (mandatory—fats and carbs significantly blunt response) • Duration: 8-16 week research cycles
Combination with GHRH Analogue: • GHRP-6: 100 mcg • Mod GRF 1-29: 100 mcg (administered simultaneously) • Frequency: 2-3 times daily • Note: Appetite stimulation remains prominent even in combinations
Managing Appetite Effects: • Pre-bed dosing may be preferred to avoid daytime hunger disruption • Have planned meal ready for 30 minutes post-injection if needed • Some researchers use appetite effect strategically for mass-gaining protocols
Timing Considerations: • Same fasting requirements as GHRP-2 (2-3 hours post-meal) • Expect significant hunger within 20-30 minutes of injection • Evening dosing allows appetite stimulation to align with dinner
Cost Consideration: GHRP-6's lower cost may allow higher-dose or longer-duration protocols within the same budget.
Combined Use
GHRP-2 + GHRP-6 Combined Use
Some research protocols have explored using both peptides, either alternating or in true combination:
Alternating Protocol: • GHRP-2 for morning/midday doses (minimise appetite disruption) • GHRP-6 for pre-bed dose (appetite effect aligns with dinner, lower cost) • Combined with Mod GRF 1-29 at each dose
Rationale: This approach attempts to balance cost-effectiveness with side effect management. However, there's no evidence of synergy between the two GHRPs themselves (they compete for the same receptor).
Scientific Perspective: Since both peptides act on GHS-R1a, combining them doesn't provide mechanistic advantage over using either alone. The "combination" is more about practical management of side effects and costs than enhanced efficacy.
Better Combinations: Rather than combining two GHRPs, research generally supports combining one GHRP with a GHRH analogue: • GHRP-2 + Mod GRF 1-29 for cleaner protocol • GHRP-6 + Mod GRF 1-29 for budget-conscious research with appetite support
With Ipamorelin: Some protocols have explored GHRP-2 with ipamorelin for an ultra-clean profile, though this also represents receptor competition rather than true synergy.
Safety Profiles
GHRP-2 Safety
GHRP-2 Safety Profile
GHRP-2 is generally considered to have a more favourable side effect profile than GHRP-6:
Common Side Effects: • Water retention (typically transient, resolving within weeks) • Injection site reactions (redness, mild pain) • Transient numbness or tingling in extremities • Mild lethargy or fatigue (usually improves with continued use) • Transient headache (especially early in use)
Hormonal Effects: • Minimal prolactin elevation (generally not clinically significant) • Mild cortisol elevation (transient, returns to baseline) • Minimal impact on thyroid function at typical doses
Metabolic Considerations: • Potential effects on glucose homeostasis (GH can impair insulin sensitivity) • May affect fasting blood glucose levels • Monitor in metabolic research or diabetic subjects
Long-Term Considerations: • Limited long-term human safety data • Theoretical concerns about continuous GH elevation (as with any GH secretagogue) • No evidence of receptor desensitisation in extended studies
Contraindications: • Active malignancy (GH may promote tumour growth) • Pregnancy and breastfeeding • Diabetic retinopathy • Known hypersensitivity to peptides
GHRP-6 Safety
GHRP-6 Safety Profile
GHRP-6 has a broader side effect profile due to its stronger ghrelin-mimetic action:
Common Side Effects: • Intense appetite stimulation (the most distinguishing feature) • Water retention (often more pronounced than GHRP-2) • Injection site reactions • Numbness and tingling in extremities • Dizziness or lightheadedness • Increased gastric acid secretion (may cause discomfort)
Hormonal Effects: • More pronounced cortisol elevation (dose-dependent) • Moderate prolactin increase (monitor for gynaecomastia symptoms) • Similar metabolic considerations as GHRP-2
Gastrointestinal: • Increased gastric motility and acid secretion • May exacerbate GERD or gastric ulcer conditions • Bloating and water retention in abdominal region
Managing Side Effects: • Lower doses reduce hormonal effects while maintaining GH release • Timing doses around meals can manage appetite effects • Starting with lower doses allows assessment of individual tolerance
Long-Term Considerations: • Extensive research history provides some reassurance • Appetite effects may persist throughout research period • Monitor cortisol and prolactin in extended protocols
Contraindications: • Same as GHRP-2 plus: • Active gastric ulcer disease • Conditions where appetite stimulation is contraindicated
The Verdict: When to Choose Which?
Choose GHRP-2 When:
- Body composition research where appetite control is important
- Anti-ageing research requiring clean hormonal profile
- Protocols where cortisol/prolactin elevation must be minimised
- Research subjects with GERD or gastric sensitivity
- Multiple daily dosing protocols where hunger would be disruptive
- Female research subjects (lower prolactin effect)
- Fat loss or cutting phase research applications
Choose GHRP-6 When:
- Recovery research where increased caloric intake supports goals
- Mass-gaining or muscle-building research protocols
- Budget-constrained research requiring larger quantities
- Cardioprotective research (specific GHRP-6 literature)
- Wound healing research (established GHRP-6 literature)
- Subjects who struggle with adequate food intake
- Research specifically studying appetite regulation
Consider Combining When:
- Alternating use for cost management while minimising daytime appetite
- Transition protocols when switching between the peptides
- Comparative studies requiring direct subject experience
- Note: No synergistic benefit from true co-administration (same receptor)
Frequently Asked Questions
Conclusion
## GHRP-2 vs GHRP-6: Summary
GHRP-2 and GHRP-6 represent the first generation of growth hormone releasing peptides and remain valuable research tools despite newer alternatives. Both effectively stimulate pulsatile GH release through GHS-R1a activation, maintaining natural feedback mechanisms unlike exogenous HGH.
The fundamental trade-off: - GHRP-2 offers cleaner GH release with minimal appetite stimulation and lower cortisol/prolactin effects, making it preferred for body composition, anti-ageing, and research requiring hormonal precision. - GHRP-6 provides robust GH release with strong appetite stimulation, making it useful for recovery, mass-gaining, and research where increased food intake supports goals—at a typically lower cost.
Key Principles for Both: - Administer on empty stomach for optimal response - Saturation dose ~100 mcg limits utility of higher doses - Combine with GHRH analogues for synergistic 5-10x GH amplification - Multiple daily doses more effective than single large doses
For Maximum GH Research Efficacy: Combine your chosen GHRP with a GHRH analogue (Mod GRF 1-29 for short action, CJC-1295 with DAC for sustained release) rather than combining two GHRPs.
*Always consult accredited suppliers and qualified healthcare professionals in your jurisdiction.*
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither GHRP-2 nor GHRP-6 is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.